|
WO1994024267A1
(fr)
*
|
1993-04-20 |
1994-10-27 |
Robinson, William, S. |
Methode et materiel de traitement de patients infectes par des agents infectieux intracellulaires
|
|
JP2000515759A
(ja)
*
|
1996-07-25 |
2000-11-28 |
サリオン・バイオロジクス・コーポレイシヨン |
腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス
|
|
JP4475683B2
(ja)
*
|
1996-07-25 |
2010-06-09 |
アメリカ合衆国 |
腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス
|
|
CA2282300C
(fr)
|
1997-02-24 |
2011-08-02 |
Therion Biologics Corporation |
Poxvirus recombine destine a une immunisation contre l'antigene associe aux tumeurs muc1
|
|
US6730512B2
(en)
*
|
1997-04-09 |
2004-05-04 |
Amdl, Inc. |
Combination immunogene therapy
|
|
TW586934B
(en)
*
|
1997-05-19 |
2004-05-11 |
Sumitomo Pharma |
Immunopotentiating composition
|
|
JP2001515052A
(ja)
*
|
1997-08-13 |
2001-09-18 |
ザ ユーエイビー リサーチ ファンデーション |
遺伝子ベクターの局所施用によるワクチン接種
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
EP2295065B1
(fr)
*
|
1998-02-20 |
2013-10-09 |
The University of Miami |
Complexe de peptide antigènes à protéines de choc thermique modifiées
|
|
WO1999043839A1
(fr)
*
|
1998-02-27 |
1999-09-02 |
The Trustees Of The University Of Pennsylvania |
Vaccins, agents d'immunotherapie et procedes pour leur utilisation
|
|
RU2244006C2
(ru)
*
|
1998-05-01 |
2005-01-10 |
Шеринг-Плау Лтд. |
Рекомбинантный вирус, экспрессирующий чужеродную днк, кодирующую кошачий cd80, кошачий ctla-4 или кошачий cd86, и его использование
|
|
US7279168B2
(en)
|
1998-05-01 |
2007-10-09 |
Texas A & M University System |
Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof
|
|
RU2377302C2
(ru)
*
|
1998-05-01 |
2009-12-27 |
Дзе Тексас Эй Энд Эм Юниверсити Систем |
Нуклеиновые кислоты, кодирующие рецептор ctla-4 кошки, вектор, клетки-хозяева, вакцины, олигонуклеотиды, полипептиды ctla-4 кошки и способы индукции и подавления иммунного ответа у кошки
|
|
EP1137792B9
(fr)
*
|
1998-12-09 |
2007-12-12 |
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
Vecteur recombine exprimant des molecules costimulantes multiples et leurs utilisations
|
|
EP1865065A1
(fr)
*
|
1998-12-09 |
2007-12-12 |
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
Vecteur recombinant exprimant plusieurs molécules costimulantes et ses utilisations
|
|
WO2001016320A1
(fr)
*
|
1999-08-30 |
2001-03-08 |
Ludwig Institute For Cancer Research |
Nonapeptides et decapeptides se fixant aux molecules hla et utilisation
|
|
DE10048710A1
(de)
*
|
1999-09-27 |
2001-10-04 |
Gabriele Pecher |
Pharmazeutische Zusammensetzung zur Behandlung und Prophylaxe von humanen Tumoren, die das Tumorantigen Muzin und/oder das Carcinoembryonale Antigen (CEA) exprimieren und ihre Verwendung
|
|
WO2001024764A2
(fr)
*
|
1999-10-06 |
2001-04-12 |
The Trustees Of The University Of Pennsylvania |
Compositions de ciblage de cellules et procedes d'utilisation de celles-ci
|
|
EP1227837B1
(fr)
|
1999-10-22 |
2008-05-21 |
Aventis Pasteur Limited |
Procede visant a provoquer et/ou stimuler une reponse immunitaire aux antigenes tumoraux
|
|
US7851212B2
(en)
*
|
2000-05-10 |
2010-12-14 |
Sanofi Pasteur Limited |
Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
|
|
GB0111442D0
(en)
*
|
2001-05-10 |
2001-07-04 |
Isis Innovation |
Method for preparing recombinant virus
|
|
US20030148973A1
(en)
*
|
2001-05-23 |
2003-08-07 |
Peter Emtage |
MAGE-A1 peptides for treating or preventing cancer
|
|
US20040091995A1
(en)
*
|
2001-06-15 |
2004-05-13 |
Jeffrey Schlom |
Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
|
|
EP1281767A3
(fr)
*
|
2001-07-31 |
2003-05-28 |
Aladar A. Szalay |
Microbes et cellules lumineuses pour le diagnostic et le traitement des tumeurs
|
|
US20030113919A1
(en)
*
|
2001-08-17 |
2003-06-19 |
Aventis Pasteur, Ltd. |
Immunogenic targets for melanoma
|
|
ES2290449T3
(es)
|
2002-04-09 |
2008-02-16 |
Sanofi Pasteur Limited |
Acido nucleico de cea modificado y vectores de expresion.
|
|
EP1369491A1
(fr)
*
|
2002-06-05 |
2003-12-10 |
Aladar A. Szalay |
Microorganismes et cellules luminescents pour le diagnostic et la thérapie de maladies asociées avec du tissu blessé ou inflammé
|
|
US20030228261A1
(en)
*
|
2002-06-05 |
2003-12-11 |
Aladar Szalay |
Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
|
|
US20040101522A1
(en)
*
|
2002-09-12 |
2004-05-27 |
Therion Biologics Corporation |
Transduced neoplastic cell preparations able to express T-cell costimulatory molecules B7.1, ICAM-1, and LFA-3 and induce immunostimulatory prophylactic and therapeutic anti-tumor effects in-vivo
|
|
AU2003278036B2
(en)
*
|
2002-10-22 |
2009-12-10 |
Aventis Pasteur Limited |
Anti-cancer vaccines and high-dose cytokines as adjuvants
|
|
US8207314B2
(en)
*
|
2003-05-16 |
2012-06-26 |
Sanofi Pasteur Limited |
Tumor antigens for prevention and/or treatment of cancer
|
|
AU2004289953B2
(en)
|
2003-06-18 |
2008-09-25 |
Genelux Corporation |
Modified recombinant vaccina viruses and other microorganisms, uses thereof
|
|
WO2005005465A2
(fr)
*
|
2003-07-08 |
2005-01-20 |
Board Of Regents, University Of Texas System |
Procedes et compositions permettant d'ameliorer des reactions immunitaires par l'intermediaire d'antigenes de rappel
|
|
ATE506444T1
(de)
*
|
2003-10-08 |
2011-05-15 |
Sanofi Pasteur Ltd |
Modifizierter cea/b7-vektor
|
|
ES2616337T3
(es)
|
2003-12-12 |
2017-06-12 |
Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors |
Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1
|
|
JP2008501360A
(ja)
*
|
2004-06-11 |
2008-01-24 |
カソリック ユニバーシティー インダストリー アカデミー コオペレーション ファウンデーション |
ＣＥＡ−特異的な細胞毒性Ｔ細胞を生成する組み換えアデノウイルスＡｄＶＣＥＡで形質導入された樹枝状細胞、及びこれを含むワクチン並びに薬剤学的組成物
|
|
EP1990410B1
(fr)
|
2006-02-22 |
2020-01-08 |
Riken |
IMMUNOTHÉRAPIE PAR L'UTILISATION D'UNE CELLULE CAPABLE DE CO-EXPRIMER UN ANTIGÈNE CIBLÉ ET LE CD1d ET PULSÉE PAR UN LIGAND DU CD1d
|
|
EP1989224B1
(fr)
|
2006-02-24 |
2010-10-20 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Peptides immunogènes et leurs méthodes d'utilisation
|
|
EP2253957B1
(fr)
|
2006-03-14 |
2013-05-15 |
Oregon Health and Science University |
Méthode pour produire une reponse contre la tuberculose
|
|
TW200819540A
(en)
|
2006-07-11 |
2008-05-01 |
Genelux Corp |
Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
|
|
EP2097517B1
(fr)
|
2006-10-16 |
2014-06-04 |
Genelux Corporation |
Virus recombinant de la vaccine de souche Lister codant pour un anticorps anti-VEGF à chaîne unique
|
|
JP5596980B2
(ja)
|
2007-02-28 |
2014-10-01 |
アメリカ合衆国 |
ブラキュリポリペプチドおよび使用方法
|
|
WO2008156655A2
(fr)
*
|
2007-06-15 |
2008-12-24 |
Genelux Corporation |
Microorganismes pour une imagerie et/ou un traitement de tumeurs
|
|
EP2173368A1
(fr)
*
|
2007-07-18 |
2010-04-14 |
Genelux Corporation |
Utilisation d'un agent chimiothérapeutique dans la préparation d'un médicament pour traiter ou améliorer un effet secondaire indésirable associé à une thérapie virale oncolytique.
|
|
JP2011513399A
(ja)
|
2008-03-03 |
2011-04-28 |
ザ ユニバーシティー オブ マイアミ |
同種癌細胞による免疫療法
|
|
CN102202687B
(zh)
|
2008-03-14 |
2015-07-29 |
赛诺菲巴斯德生物制剂有限责任公司 |
复制缺陷型黄病毒疫苗和疫苗载体
|
|
JP2011515399A
(ja)
|
2008-03-20 |
2011-05-19 |
ユニバーシティー オブ マイアミ |
熱ショックタンパクｇｐ９６ワクチン接種及びそれを用いた方法
|
|
WO2010005474A1
(fr)
*
|
2008-06-16 |
2010-01-14 |
Emergent Product Development Gaithersburg Inc. |
Virus de la vaccine ankara (mva) recombinant modifié exprimant des antigènes polypeptidiques de chlamydia
|
|
US20110280895A1
(en)
|
2008-11-28 |
2011-11-17 |
Riken |
IMMUNOTHERAPEUTIC METHOD USING ALLO-CELLS WHICH CO-EXPRESS CD1d AND TARGET ANTIGEN
|
|
DE102008055194A1
(de)
|
2008-12-30 |
2010-07-08 |
Federal-Mogul Wiesbaden Gmbh |
Gleitelement
|
|
US8664183B2
(en)
|
2009-02-27 |
2014-03-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
SPANX-B polypeptides and their use
|
|
AU2010236206B2
(en)
|
2009-04-17 |
2016-10-20 |
Globeimmune, Inc. |
Combination immunotherapy compositions against cancer and methods
|
|
EP3360566B1
(fr)
|
2009-11-20 |
2019-12-25 |
Oregon Health&Science University |
Procedes destines a detecter une infection par mycrobacterium tuberculosis
|
|
ES2625406T3
(es)
|
2010-03-25 |
2017-07-19 |
Oregon Health & Science University |
Glicoproteínas de CMV y vectores recombinantes
|
|
WO2011129379A1
(fr)
|
2010-04-13 |
2011-10-20 |
独立行政法人理化学研究所 |
Nouvel anticorps monoclonal anti-hsp90
|
|
JP5603486B2
(ja)
*
|
2010-06-10 |
2014-10-08 |
インターベット インターナショナル ベー． フェー． |
抗腫瘍組成物
|
|
EP3153861A3
(fr)
|
2010-08-06 |
2017-06-07 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Biomarqueurs destinés à prédire la réponse à un vaccin contre le cancer
|
|
AU2012217723A1
(en)
|
2011-02-15 |
2013-08-29 |
Immune Design Corp. |
Methods for enhancing immunogen specific immune responses by vectored vaccines
|
|
EP3632463A1
(fr)
|
2011-04-08 |
2020-04-08 |
Immune Design Corp. |
Compositions immunogènes et leurs procédés d'utilisation pour induire des réponses immunitaires humorales et cellulaires
|
|
CA2836299A1
(fr)
|
2011-04-15 |
2012-10-18 |
Genelux Corporation |
Souches clonales de virus attenues de la vaccine et leurs procedes d'utilisation
|
|
SI2691530T1
(en)
|
2011-06-10 |
2018-08-31 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
|
CA2789539A1
(fr)
|
2011-09-12 |
2013-03-12 |
International Aids Vaccine Initiative |
Immunoselection de virus de la stomatite vesiculeuse recombinant exprimant des proteines hiv-1 en neutralisant largement les anticorps
|
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
|
US9895435B2
(en)
|
2012-05-16 |
2018-02-20 |
Immune Design Corp. |
Vaccines for HSV-2
|
|
EP2679596B1
(fr)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
Variante de la protéine env du VIH-1
|
|
US20150224181A1
(en)
|
2012-09-14 |
2015-08-13 |
The United States Of America As Represented By The Secretary Department Of Health And Human Se |
Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
|
|
WO2014140938A2
(fr)
|
2013-03-14 |
2014-09-18 |
Centre Hospitalier Universitaire Vaudois |
Méthodes immunologiques
|
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
|
EP2873423B1
(fr)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Trimères de glycoprotéines d'enveloppe du vih -1 soluble
|
|
CA2939093A1
(fr)
|
2014-02-14 |
2015-08-20 |
Immune Design Corp. |
Immunotherapie du cancer par combinaison de stimulation immunitaire locale et systemique
|
|
US20170196954A1
(en)
|
2014-07-15 |
2017-07-13 |
Immune Design Corp. |
Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
|
|
AU2016215175B2
(en)
|
2015-02-06 |
2021-09-16 |
Heat Biologics, Inc. |
Vector co-expressing vaccine and costimulatory molecules
|
|
KR20170138996A
(ko)
|
2015-02-25 |
2017-12-18 |
메모리얼 슬로안-케터링 캔서 센터 |
고형 종양을 위한 단일면역요법으로서 또는 면역 체크포인트 차단제와 조합된 불활성화 비복제성 변형 백시니아 바이러스 안카라의 용도
|
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
US9931394B2
(en)
|
2015-03-23 |
2018-04-03 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
EP3283088A4
(fr)
|
2015-04-17 |
2018-10-24 |
Memorial Sloan-Kettering Cancer Center |
Utilisation de mva ou de mvadeltae3l en tant qu'agents immunothérapeutiques contre des tumeurs solides
|
|
WO2016187027A1
(fr)
*
|
2015-05-15 |
2016-11-24 |
Reber Genetics Co., Ltd. |
Nouveaux vecteurs de baculovirus et procédés d'utilisation
|
|
US11365230B2
(en)
|
2015-11-09 |
2022-06-21 |
Immune Design Corp. |
Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof
|
|
WO2017120204A2
(fr)
|
2016-01-05 |
2017-07-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combinaison d'un inhibiteur d'histone désacétylase et d'une immunothérapie
|
|
WO2017136342A1
(fr)
|
2016-02-02 |
2017-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fulvestrant induisant la lyse cytotoxique à médiation immunitaire des cellules cancéreuses
|
|
SG11201806976UA
(en)
|
2016-02-23 |
2018-09-27 |
Immune Design Corp |
Multigenome retroviral vector preparations and methods and systems for producing and using same
|
|
JP7025339B2
(ja)
|
2016-02-25 |
2022-02-24 |
メモリアル スローン ケタリング キャンサー センター |
癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
|
|
JP7034080B2
(ja)
|
2016-02-25 |
2022-03-11 |
メモリアル スローン ケタリング キャンサー センター |
ヒトｆｌｔ３ｌを発現する組換えｍｖａまたはｍｖａδｅ３ｌおよび固形腫瘍に対する免疫療法薬としてのそれらの使用
|
|
IL262366B2
(en)
|
2016-04-15 |
2024-07-01 |
Alpine Immune Sciences Inc |
Immunomodulatory proteins and CD80 variants and their uses
|
|
CA3019199A1
(fr)
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Proteines immunomodulatrices a variants du ligand icos et leurs utilisations
|
|
WO2018022945A1
(fr)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Protéines immunomodulatrices à variants de cd112 et utilisations associées
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
CA3032120A1
(fr)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Proteines immunomodulatrices a variants de cd155 et leurs utilisations
|
|
CA3040123A1
(fr)
|
2016-10-11 |
2018-04-19 |
University Of Miami |
Vecteurs et cellules de vaccin pour immunite contre le virus zika
|
|
CA3053804A1
(fr)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Proteines immunomodulatrices de variants de pd-l1 et utilisations associees
|
|
JP7386083B2
(ja)
|
2017-03-16 |
2023-11-24 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ｃｄ８０バリアント免疫調節タンパク質及びその使用
|
|
US11732022B2
(en)
|
2017-03-16 |
2023-08-22 |
Alpine Immune Sciences, Inc. |
PD-L2 variant immunomodulatory proteins and uses thereof
|
|
US11254712B2
(en)
|
2017-03-30 |
2022-02-22 |
The University Of Queensland |
Chimeric molecules and uses thereof
|
|
CA3058938A1
(fr)
|
2017-04-04 |
2018-10-11 |
Heat Biologics, Inc. |
Vaccination intratumorale
|
|
US11242509B2
(en)
|
2017-05-12 |
2022-02-08 |
Memorial Sloan Kettering Cancer Center |
Vaccinia virus mutants useful for cancer immunotherapy
|
|
US12076369B2
(en)
|
2017-09-01 |
2024-09-03 |
The Frances Crick Institute Limited |
Immunoregulatory molecules and uses therefor
|
|
CA3198255A1
(fr)
|
2017-10-10 |
2019-04-18 |
Alpine Immune Sciences, Inc. |
Proteines immunomodulatrices de variants de ctla-4 et leurs utilisations
|
|
BR112020007542A2
(pt)
|
2017-10-18 |
2020-12-01 |
Alpine Immune Sciences, Inc. |
proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
|
|
WO2019136179A1
(fr)
|
2018-01-03 |
2019-07-11 |
Alpine Immune Sciences, Inc. |
Protéines immunomodulatrices multi-domaine et leurs méthodes d'utilisation
|
|
CN111684198B
(zh)
*
|
2018-02-09 |
2022-09-23 |
株式会社龙野 |
填充装置
|
|
US12065476B2
(en)
|
2018-06-15 |
2024-08-20 |
Alpine Immune Sciences, Inc. |
PD-1 variant immunomodulatory proteins and uses thereof
|
|
MX2021003013A
(es)
|
2018-09-15 |
2021-08-11 |
Memorial Sloan Kettering Cancer Center |
Poxvirus recombinantes para inmunoterapia contra cáncer.
|
|
MA53651A
(fr)
|
2018-09-19 |
2021-07-28 |
Alpine Immune Sciences Inc |
Méthodes et utilisations de protéines de fusion de variant cd80 et constructions associées
|
|
WO2020072833A1
(fr)
*
|
2018-10-04 |
2020-04-09 |
Sqz Biotechnologies Company |
Administration intracellulaire de biomolécules pour améliorer la fonction de cellule présentatrice d'antigène
|
|
EP3887394A2
(fr)
|
2018-11-30 |
2021-10-06 |
Alpine Immune Sciences, Inc. |
Protéines immunomodulatrices à variants cd86 et leurs utilisations
|
|
AU2020257238A1
(en)
|
2019-04-17 |
2021-12-02 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant ICOS Ligand (ICOSL) fusion proteins
|
|
US20220313761A1
(en)
|
2019-05-14 |
2022-10-06 |
National University Corporation Tottori University |
Vaccinia virus that induces cell fusion and use thereof
|
|
WO2021029368A1
(fr)
|
2019-08-09 |
2021-02-18 |
国立研究開発法人理化学研究所 |
Utilisation combinée de cellules vecteur adjuvant artificiel et d'immunostimulant
|
|
CA3178882A1
(fr)
|
2020-05-08 |
2021-11-11 |
Alpine Immune Sciences, Inc. |
Proteines immunomodulatrices inhibitrices d'april et de baff et leurs procedes d'utilisation
|
|
WO2022107705A1
(fr)
|
2020-11-17 |
2022-05-27 |
国立大学法人鳥取大学 |
Nouveau virus de la vaccine recombiné génique et son utilisation
|
|
JPWO2022230971A1
(fr)
|
2021-04-30 |
2022-11-03 |
|
|
|
EP4333869A1
(fr)
|
2021-05-07 |
2024-03-13 |
Alpine Immune Sciences, Inc. |
Procédés de dosage et de traitement avec une protéine immunomodulatrice de fusion taci-fc
|
|
EP4490173A1
(fr)
|
2022-03-07 |
2025-01-15 |
Alpine Immune Sciences, Inc. |
Protéines immunomodulatrices de polypeptides cd80 variants, thérapies cellulaires associées et méthodes et utilisations associés
|
|
KR20250048615A
(ko)
|
2022-07-08 |
2025-04-09 |
바이로미슬, 인크. |
종양용해 백시니아 바이러스 및 재조합 바이러스 및 그의 사용 방법
|
|
AU2023356958A1
(en)
|
2022-10-04 |
2025-04-03 |
Alpine Immune Sciences, Inc. |
Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases
|